Strahlentherapie und Onkologie

, Volume 189, Issue 3, pp 216–222

Xerostomia after radiotherapy

What matters—mean total dose or dose to each parotid gland?
  • S. Tribius
  • J. Sommer
  • C. Prosch
  • A. Bajrovic
  • A. Muenscher
  • M. Blessmann
  • A. Kruell
  • C. Petersen
  • M. Todorovic
  • P. Tennstedt
Original article

Abstract

Purpose

Xerostomia is a debilitating side effect of radiotherapy in patients with head and neck cancer. We undertook a prospective study of the effect on xerostomia and outcomes of sparing one or both parotid glands during radiotherapy for patients with squamous cell carcinoma of the head and neck.

Methods and materials

Patients with locally advanced squamous cell carcinoma of the head and neck received definitive (70 Gy in 2 Gy fractions) or adjuvant (60–66 Gy in 2 Gy fractions) curative-intent radiotherapy using helical tomotherapy with concurrent chemotherapy if appropriate. Group A received < 26 Gy to the left and right parotids and group B received < 26 Gy to either parotid.

Results

The study included 126 patients; 114 (55 in group A and 59 in group B) had follow-up data. There were no statistically significant differences between groups in disease stage. Xerostomia was significantly reduced in group A vs. group B (p = 0.0381). Patients in group A also had significantly less dysphagia. Relapse-free and overall survival were not compromised in group A: 2-year relapse-free survival was 86% vs. 72% in group B (p = 0.361); 2-year overall survival was 88% and 76%, respectively (p = 0.251).

Conclusion

This analysis suggests that reducing radiotherapy doses to both parotid glands to < 26 Gy can reduce xerostomia and dysphagia significantly without compromising survival. Sparing both parotids while maintaining target volume coverage and clinical outcome should be the treatment goal and reporting radiotherapy doses delivered to the individual parotids should be standard practice.

Keywords

Helical tomotherapy Radiotherapy, intensity modulated Head and neck cancer Survival analysis Parotid gland 

Xerostomie nach Strahlentherapie

Was ist klinisch relevant – die durchschnittliche Gesamtdosis oder die Dosis in jeder Parotis?

Zusammenfassung

Ziel

Für Patienten mit Kopf-Hals-Tumoren ist die Xerostomie nach Strahlentherapie ein häufiges Problem. Im Rahmen einer prospektiven Studie haben wir untersucht, inwieweit die Schonung nur einer oder beider Parotiden das Ausmaß der Xerostomie und das Therapieergebnis beeinflusst.

Patienten und Methoden

Patienten mit lokal fortgeschrittenem Plattenepithelkarzinom im Kopf-Hals-Bereich wurden primär (70 Gy, 2 Gy pro Fraktion) oder adjuvant (60–66 Gy, 2 Gy pro Fraktion) mit kurativer Intention mit der helikalen Tomotherapie bestrahlt. Bei entsprechender Indikation wurde simultan eine platinbasierte Chemotherapie appliziert. Die Parotiden der Patienten der Gruppe A erhielten beide jeweils < 26 Gy, während in Gruppe B nur eine der beiden Parotiden mit < 26 Gy bestrahlt wurde.

Ergebnisse

126 Patienten wurden eingeschlossen, von denen 114 systematisch nachgesorgt werden konnten, 55 in Gruppe A und 59 in Gruppe B. Bezüglich der Tumorstadien bestand statistisch zwischen den Gruppen kein Unterschied. Die Xerostomierate war in Gruppe A signifikant geringer als in Gruppe B (p = 0,0381). Bei signifikant weniger Patienten der Gruppe A kam es zu einer Dysphagie (p = 0,0032). Das rezidivfreie Überleben und das Gesamtüberleben waren nicht beeinträchtigt; das rezidivfreie Überleben nach 2 Jahren betrug 86% in Gruppe A versus 72% in Gruppe B (p = 0,361); das Gesamtüberleben nach 2 Jahren lag bei 88% in Gruppe A versus 76% in Gruppe B (p = 0,251).

Schlussfolgerung

Bei der Diskussion um Parotisschonung/Dosisbelastung ist es entscheidend, dass jede Parotis individuell zu betrachten ist und nicht der Mittelwert über beide. Diese Ergebnisse zeigen, dass siginifikant weniger Patienten eine Xerostomie und Dysphagie entwickeln, wenn beide Parotiden mit < 26 Gy belastet werden, ohne dass das Gesamtüberleben oder das rezidivfreie Überleben negativ beeinträchtigt werden.

Schlüsselwörter

Helikale Tomotherapie Intensitätsmodulierte Strahlentherapie Kopf-Hals-Karzinom Xerostomie Parotis 

References

  1. 1.
    Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952PubMedCrossRefGoogle Scholar
  2. 2.
    Brotherston DC, Poon I, Le T et al (2012) Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck doi 10.1002/hed.22930Google Scholar
  3. 3.
    Chencharick JD, Mossman KL (1983) Nutritional consequences of the radiotherapy of head and neck cancer. Cancer 51:811–815PubMedCrossRefGoogle Scholar
  4. 4.
    Dijkema T, Raaijmakers CP, Ten Haken RK et al (2010) Parotid gland function after radiotherapy: the combined Michigan and Utrecht experience. Int J Radiat Oncol Biol Phys 78:449–453PubMedCrossRefGoogle Scholar
  5. 5.
    Dreyer JO, Sakuma Y, Seifert G (1989) Radiation-induced sialadenitis. Stage classification and immunohistology. Pathologe 10:165–170 (in German)PubMedGoogle Scholar
  6. 6.
    Eisbruch A, Ten Haken RK, Kim HM et al (1999) Volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45:577–587PubMedCrossRefGoogle Scholar
  7. 7.
    Fakhrian K, Thamm R, Knapp S et al (2012) Radio(chemo)therapy in the management of squamous cell carcinoma of cervical lymph nodes from an unknown primary site. A retrospective analysis. Strahlenther Onkol 188:56–61PubMedCrossRefGoogle Scholar
  8. 8.
    García-Peris P, Parón L, Velasco C et al (2007) Long-term prevalence of oropharyngeal dysphagia in head and neck cancer patients: impact on quality of life. Clin Nutr 26:710–717PubMedCrossRefGoogle Scholar
  9. 9.
    Kam MK, Leung SF, Zee B et al (2007) Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25:4873–4879PubMedCrossRefGoogle Scholar
  10. 10.
    Konings AW, Coppes RP, Vissink A (2005) On the mechanism of salivary gland radiosensitivity. Int J Radiat Oncol Biol Phys 62:1187–1194PubMedCrossRefGoogle Scholar
  11. 11.
    Kreppel M, Drebber U, Eich HT et al (2011) Combined-modality treatment in advanced oral squamous cell carcinoma: primary surgery followed by adjuvant concomitant radiochemotherapy. Strahlenther Onkol 187:555–560PubMedCrossRefGoogle Scholar
  12. 12.
    Lee NY, Arruda FF de, Puri DR et al (2006) A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66:966–974PubMedCrossRefGoogle Scholar
  13. 13.
    Marur S, D’Souza G, Westra WH et al (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781–789PubMedCrossRefGoogle Scholar
  14. 14.
    Maurer J, Hipp M, Schäfer C, Kölbl O (2011) Dysphagia. Impact on quality of life after radio(chemo)therapy of head and neck cancer. Strahlenther Onkol 187:744–749PubMedCrossRefGoogle Scholar
  15. 15.
    Murthy V, Master Z, Gupta T et al (2010) Helical tomotherapy for head and neck squamous cell carcinoma: dosimetric comparison with linear accelerator-based step-and-shoot IMRT. J Cancer Res Ther 6:194–198PubMedCrossRefGoogle Scholar
  16. 16.
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (2011) Head and Neck Cancers version 2.2011. Available at: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed 07 January 2013Google Scholar
  17. 17.
    Nutting CM, Morden JP, Harrington KJ et al (2011) PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12:127–136PubMedCrossRefGoogle Scholar
  18. 18.
    Pow EH, Kwong DL, McMillan AS et al (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66:981–991PubMedCrossRefGoogle Scholar
  19. 19.
    Rades D, Seibold ND, Gebhard MP et al (2011) Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187:626–632PubMedCrossRefGoogle Scholar
  20. 20.
    Rades D, Ulbricht T, Hakim SG, Schild SE (2012) Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity. Strahlenther Onkol 188:42–48PubMedCrossRefGoogle Scholar
  21. 21.
    Ringash J, Warde P, Lockwood G et al (2005) Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys 61:1403–1407PubMedCrossRefGoogle Scholar
  22. 22.
    Roesink JM, Schipper M, Busschers W et al (2005) A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: implications for future trials. Int J Radiat Oncol Biol Phys 63:1006–1009PubMedCrossRefGoogle Scholar
  23. 23.
    Semrau R, Temming S, Preuss SF et al (2011) Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel: a phase II study. Strahlenther Onkol 187:645–650PubMedCrossRefGoogle Scholar
  24. 24.
    Tribius S, Ihloff AS, Rieckmann T et al (2011) Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett 304:71–79PubMedCrossRefGoogle Scholar
  25. 25.
    Vergeer MR, Doornaert PA, Rietveld DH et al (2009) Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 74:1–8PubMedCrossRefGoogle Scholar
  26. 26.
    Vissink A, Jansma J, Spijkervet FK et al (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14:199–212PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2013

Authors and Affiliations

  • S. Tribius
    • 1
  • J. Sommer
    • 1
  • C. Prosch
    • 1
  • A. Bajrovic
    • 1
  • A. Muenscher
    • 2
  • M. Blessmann
    • 3
  • A. Kruell
    • 1
  • C. Petersen
    • 1
  • M. Todorovic
    • 4
  • P. Tennstedt
    • 5
  1. 1.Department of Radiation OncologyUniversity Medical Center Hamburg–EppendorfHamburgGermany
  2. 2.Department of Otorhinolaryngology and Head and Neck SurgeryUniversity Medical Center Hamburg–EppendorfHamburgGermany
  3. 3.Department of Oral and Maxillofacial SurgeryUniversity Medical Center Hamburg–EppendorfHamburgGermany
  4. 4.Department of Medical PhysicsUniversity Medical Center Hamburg–EppendorfHamburgGermany
  5. 5.Martini-Clinic, Prostate Cancer CenterUniversity Medical Center Hamburg–EppendorfHamburgGermany

Personalised recommendations